{"id":"mn-rgp120-hiv-1-and-gne8-rgp120-hiv-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, induration)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL3672477","moleculeType":"Small molecule","molecularWeight":"317.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These vaccines contain recombinant gp120 proteins from different HIV-1 strains (MN and GNE8) that serve as immunogens to stimulate both humoral and cellular immune responses against the HIV-1 envelope. By exposing the immune system to these viral surface proteins, the vaccines aim to generate neutralizing antibodies and T-cell responses that can recognize and eliminate HIV-1-infected cells or prevent infection.","oneSentence":"MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 are recombinant gp120 envelope protein vaccines designed to elicit immune responses against HIV-1 by presenting the viral surface antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:51.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 prevention in at-risk populations"}]},"trialDetails":[{"nctId":"NCT00000871","phase":"PHASE2","title":"A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00000884","phase":"PHASE1","title":"A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":84},{"nctId":"NCT00000879","phase":"PHASE1","title":"A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":48},{"nctId":"NCT00007332","phase":"PHASE2","title":"Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":330},{"nctId":"NCT00002402","phase":"PHASE1","title":"A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines","status":"COMPLETED","sponsor":"VaxGen","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00002441","phase":"PHASE3","title":"Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection","status":"COMPLETED","sponsor":"VaxGen","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MN rgp120/HIV-1 and GNE8 rgp120/HIV-1","genericName":"MN rgp120/HIV-1 and GNE8 rgp120/HIV-1","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 are recombinant gp120 envelope protein vaccines designed to elicit immune responses against HIV-1 by presenting the viral surface antigen. Used for HIV-1 prevention in at-risk populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}